Acceptability and Safety of MR-C-014 in Persons With Neuromyelitis Optica Spectrum Disorder

Part of paid clinical trials in Atlanta, Georgia.

Sponsor
MedRhythms, Inc.
Study ID
NCT06374264
Status
Enrolling By Invitation

Conditions

  • Neuromyelitis Optica Spectrum Disorder

Eligibility Criteria

Sex
ALL
Age
18 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

  • MR-C-014 — DEVICE
    Use of device 3 times per week (for 30 minutes) for 8 weeks - for a total of 24 sessions.

Study Details

The purpose of this proof of concept study is to assess the acceptability and safety of MR-C-014 in persons with Neuromyelitis optica spectrum disorder (NMOSD) who have a gait deficit.

Key Dates

Start date
Nov 12, 2024
Status verified
Dec 2025
Primary completion
Mar 31, 2026
Completion
Mar 31, 2026

Study Design

Enrollment
30 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Intervention
    Participants will be asked to use MR-C-014 for 24 sessions (30 minutes each), 3 times a week for 8 weeks.

Primary Outcome Measure

Participant acceptability of MR-C-014 [ Time Frame: Intervention period (of up to 8 weeks) ]

Locations (2)

FacilityCityStateZIPSite coordinators
Sheperd CenterAtlantaGeorgia30309-
Massachusetts General HospitalBostonMassachusetts02114-

Find similar trials in Atlanta, GA

By research site
Sheperd Center· Atlanta, GAMassachusetts General Hospital· Boston, MA

Related Studies